May 2 |
Novocure Reports First Quarter 2024 Financial Results
|
May 1 |
NovoCure Q1 2024 Earnings Preview
|
Apr 25 |
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
|
Apr 24 |
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
|
Apr 5 |
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
|
Apr 1 |
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
|
Apr 1 |
Novocure to Report First Quarter 2024 Financial Results
|
Mar 30 |
Why NovoCure Stock Soared 18.3% This Week
|
Mar 28 |
Why Novocure Stock Is Jumping Today
|
Mar 28 |
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?
|